Cangrelor in endovascular stroke treatment with emergent carotid artery stenting (CANCAS)
Key facts
- Where
- Graz, Innsbruck és Salzburg, AusztriaSee the 3 sites
- Phase
- 2. fázis
Where in Ausztria
- Medical University of GrazGraz, AusztriaTaking people
- Medizinische Universitaet InnsbruckInnsbruck, AusztriaTaking people
- Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbHSalzburg, AusztriaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Medical University Of Graz
- Trial code
- EU 2025-521564-35-00
- Record updated
- 2026. július 22.
- Original description
To assess the safety and efficacy of IV Cangrelor in patients with acute ischaemic stroke and large vessel occlusion of the intracranial carotid artery or first two segments of the middle cerebral artery (carotid artery territory) and concomitant symptomatic atherosclerotic extracranial carotid artery stenosis (≥50%) requiring mechanical thrombectomy and emergent extracranial carotid artery stenting.Read full original descriptionShow less
To assess the safety and efficacy of IV Cangrelor in patients with acute ischaemic stroke and large vessel occlusion of the intracranial carotid artery or first two segments of the middle cerebral artery (carotid artery territory) and concomitant symptomatic atherosclerotic extracranial carotid artery stenosis (≥50%) requiring mechanical thrombectomy and emergent extracranial carotid artery stenting.
Inclusion: Adult patients (≥18 years of age); Large vessel occlusion stroke of the anterior cerebral circulation (carotid artery territory); Concomitant ipsilateral atherosclerotic carotid artery stenosis ≥50% requiring mechanical thrombectomy and emergent carotid artery stenting.
Exclusion: Active pre-treatment with a P2Y12 inhibitor (e.g. Clopidogrel, Ticagrelor, Prasugrel; Pre-treatment with oral anticoagulants in a therapeutic dosage; Prohibited concomitant therapies; High intra- or extracranial bleeding risk according to the judgement of the treating stroke physicians (history of severe bleeding disorders, known haemophilia, severe liver disease, thrombocytopenia <100,000/µL, coagulation factor abnormalities, recent major surgery, recent major trauma, large brain infarct size; Uncontrolled hypertension; The patient’s medical history reveals a known allergy to any of the medications being used or their constituents, or to medications with a similar chemical structure; Non-atherosclerotic carotid artery stenosis (e.g. dissection); Known pregnancy (for women with childbearing potential a negative pregnancy test is required); Simultaneous participation in another interventional clinical trial.